A/DT
germline/NN
TaqI/NN
restriction/NN
fragment/NN
length/NN
polymorphism/NN
in/IN
the/DT
progesterone/NN
receptor/NN
gene/NN
in/IN
ovarian/JJ
carcinoma/NN
[/(
see/VB
comments/NNS
]/)

Clinical/JJ
outcome/NN
in/IN
ovarian/JJ
carcinoma/NN
is/VBZ
predicted/VBN
by/IN
progesterone/NN
receptor/NN
status/NN
,/,
indicating/VBG
an/DT
endocrine/JJ
aspect/NN
to/TO
this/DT
disease/NN
./.
=====
Peripheral/JJ
leucocyte/NN
genomic/JJ
DNAs/NNS
were/VBD
obtained/VBN
from/IN
41/CD
patients/NNS
with/IN
primary/JJ
ovarian/JJ
carcinoma/NN
and/CC
83/CD
controls/NNS
from/IN
Ireland/NNP
,/,
as/RB
well/RB
as/IN
from/IN
26/CD
primary/JJ
ovarian/JJ
carcinoma/NN
patients/NNS
and/CC
101/CD
controls/NNS
in/IN
Germany/NNP
./.
=====
Southern/NN
analysis/NN
using/VBG
a/DT
human/JJ
progesterone/NN
receptor/NN
(/(
hPR/NN
)/)
cDNA/NN
probe/NN
identified/VBD
a/DT
germline/NN
TaqI/NN
restriction/NN
fragment/NN
length/NN
polymorphism/NN
(/(
RFLP/NN
)/)
defined/VBN
by/IN
two/CD
alleles/NNS
:/:
T1/NN
,/,
represented/VBN
by/IN
a/DT
2.7/CD
kb/NN
fragment/NN
;/:
and/CC
T2/NN
,/,
represented/VBN
by/IN
a/DT
1.9/CD
kb/NN
fragment/NN
and/CC
characterised/VBN
by/IN
an/DT
additional/JJ
TaqI/NN
restriction/NN
site/NN
with/IN
respect/NN
to/TO
T1/NN
./.
=====
An/DT
over-representation/NN
of/IN
T2/NN
in/IN
ovarian/JJ
cancer/NN
patients/NNS
compared/VBN
with/IN
controls/NNS
in/IN
the/DT
pooled/JJ
Irish/German/NNP
population/NN
(/(
P/NN
</JJR
0.025/CD
)/)
was/VBD
observed/VBN
./.
=====
A/DT
difference/NN
(/(
P/NN
</JJR
0.02/CD
)/)
in/IN
the/DT
distribution/NN
of/IN
the/DT
RFLP/NN
genotypes/NNS
between/IN
Irish/NNP
and/CC
German/NNP
control/JJ
populations/NNS
was/VBD
also/RB
observed/VBN
./.
=====
The/DT
allele/NN
distributions/NNS
could/MD
not/RB
be/VB
shown/VBN
to/TO
differ/VB
significantly/RB
from/IN
Hardy-Weinberg/JJ
distribution/NN
in/IN
any/DT
subgroup/NN
./.
=====
Using/VBG
hPR/NN
cDNA/NN
region-specific/JJ
probes/NNS
,/,
the/DT
extra/JJ
TaqI/NN
restriction/NN
site/NN
was/VBD
mapped/VBN
to/TO
intron/NN
G/NN
of/IN
the/DT
hPR/NN
gene/NN
./.